COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...
FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...
New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease ...
Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few ...
Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of EGFR-mutated lung cancer ...
Phase 3 trials for three different agents show substantial reductions in kidney function decline and other improvements ...
One of the most representative products from Hengrui Pharma's ADC research and development platform, trastuzumab rezetecan is being developed for more than ten indications, including breast, lung, ...
Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while ...
A computational and synthesis study prioritized benzohydrazide compounds 3d and 3f for experimental EGFR testing, while the lack of biological assays means their binding and anticancer activity remain ...
In the ALK-rearranged NCI-H3122 model, ATNM-400 plus crizotinib achieved 97% TGI, compared with 50% for ATNM-400, 55% for crizotinib and 26% for patritumab deruxtecan alone. ATNM-400-containing ...
A new review in Genes & Diseases outlines how co-targeting EGFR alongside other tumor-driving molecules, delivered via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results